Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTXM83 plus CHOP vs reference rituximab plus CHOP in first-line DLBCL
IRCT2014121612398N5Phase 3Completed
- Sponsor
- Actoverco
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Actoverco. Started Jun 2015; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on IRCT2014121612398N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2014121612398N5.